William M. Burns F. Hoffmann-La Roche Ltd Grenzacherstrasse 124 CH-4070 Basel, SwitzerlandAspreva Pharmaceuticals CORP • November 6th, 2007 • Pharmaceutical preparations
Re: Fourth Amendment to the CellCept® Collaboration and Promotion Agreement by and between Aspreva Pharmaceuticals SA (“Aspreva”), F.Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, “Roche”), dated as of July 18, 2003, as amended (the “Agreement”)
William M. Burns F. Hoffmann-La Roche Ltd Grenzacherstrasse 124 CH-4070 Basel, SwitzerlandCollaboration Agreement • November 6th, 2007 • Aspreva Pharmaceuticals CORP • Pharmaceutical preparations
As a follow up to our recent discussions with you and your team regarding our CellCept® Collaboration and Promotion Agreement dated July 18, 2003, as amended (“Collaboration Agreement”), this letter (“Letter Agreement”) sets forth certain understandings and agreements reached by Aspreva and Roche with respect to activities undertaken by Roche to develop and commercialize CellCept for autoimmune indications (“ROW Activities”). The ROW Activities consist of the following:
